

General:

- Id of document version: **12540611**
- Status of the document <ep-bulletin>: **Replacement of data for an application already published**
- Changed tag from previous publication of document <B002EP><ep-chgt-info>: **B475=N,20180302**
- Publication number of the document (EPO or WIPO) <B110>: **2295035**
- Kind of document <B130>: **B1**
- EPO Application number <B210>: **10173506.6**
- Application filing date <B220>: **2008.11.04**
- Date of refusal of application <B235>:
- Date of withdrawal of application <B235>:
- Date of application deemed withdrawn <B237>:
- Date of receipt of request for re-establishment of rights <B238EP>:
- Date of decision for re-establishment of rights <B238>:
- Date of making available to the public by printing or similar process of an unexamined patent document, on which no grant has taken place on or before the said date <B430>: **2011.03.16**
- Date of making available to the public by printing or similar process of a patent document on which grant has taken place on or before the said date <B450><date>: **2016.05.18**
- Number of the EPO Bulletin in which the mention of the grant is published. <B450><bnun>: **201620**
- Date of rejection of the opposition procedure <B787>:
- Date of termination of the opposition procedure <B788>:
- Due date for translation: **2016.08.18**
- Text when the inventor has agreed to waive his entitlement to designation. <B009EP><text[j]>:
- Date of reception of document: **2018.04.06**
- Date of publication <B140>: **2018.04.04**

Priority <B300>:

Number(s) assigned to priority application(s) <B310>:	Date(s) of filing of priority application(s) <B320>:	National property office allotting the priority application number or the organization allotting the regional priority application Number (WO for PCT) – country code <B330>:
	2007.11.06	US

Lapse <B472>:

No lapse.

Classification <B500>:

IPC (8) as one fixed length field of 50 positions <B510EP><text>:	Edition of IPC (IPC version) <B516>:
A61K 9/00 20060101AFI20120626BHEP	8
A61K 9/20 20060101ALI20120626BHEP	8
A61K 31/216 20060101ALI20120626BHEP	8
A61K 31/41 20060101ALN20120626BHEP	8

Title <B540>:

No title.

Division <B620> or <B620EP>:

Application number of the parent application <B620><anum> or <B620EP><anum>:	Publication number of the parent application <B620><pnum> or <B620EP><pnum>:	Date of receipt <B620><date> or <B620EP><date>:	Parent <B620> or <B620EP>:
08848154.4		2008.11.04	0
16157767.1		2016.02.29	1

EPO Customer <B710>&<B720>&<B730>&<B740>:

Name <snm>:	Al-Fayoumi, Suliman	EPO number of the customer <iid>:	
Address <street>, <city>, <ctry>:	31 Knollwood Drive Morristown, NJ 07960 US		
Customer type:	Inventor	Status:	0
Name <snm>:	Hu, Jiahui	EPO number of the	

		customer <iid>:	
Address <street>, <city>, <ctry>:	92 Bradley Lane Bridgewater, NJ 08807 US		
Customer type:	Inventor	Status:	0

Name <snm>:	Kumaraperumal, Natrajan	EPO number of the customer <iid>:	
Address <street>, <city>, <ctry>:	40-B Byrne Court Wayne, NJ 07470 US		
Customer type:	Inventor	Status:	0

Name <snm>:	Larbig, Karen Dorothee	EPO number of the customer <iid>:	101151589
Address <street>, <city>, <ctry>:	Novartis Pharma AG Patent Department 4002 Basel CH		
Customer type:	Attorney / Agent	Status:	0

Name <snm>:	Novartis AG	EPO number of the customer <iid>:	100189475
Address <street>, <city>, <ctry>:	Lichtstrasse 35 4056 Basel CH		
Customer type:	Grantees	Status:	0

Name <snm>:	Royce, Alan Edward	EPO number of the customer <iid>:	
Address <street>, <city>, <ctry>:	RR 4 Box 9LE Saylorsburg, PA 18353 US		
Customer type:	Inventor	Status:	0

Name <snm>:	Ruegger, Colleen	EPO number of the customer <iid>:	
--------------------------	------------------	--	--

Address <street>, <city>, <ctry>:	89 Poplar Drive Morris Plains, NJ 07950 US		
Customer type:	Inventor	Status:	0

Name <snm>:	Zannou, Erika Aina	EPO number of the customer <iid>:	
Address <street>, <city>, <ctry>:	12 Mary Ellen Drive Edison, NJ 08820 US		
Customer type:	Inventor	Status:	0

Opposition <B780>:

Serial number of the opposition <B781><dnum>:	01	Date of opposition, Date of receipt for 'filed' and 'admissible' oppositions, Date of legal effect for 'inadmissible' and 'deemed not, to be filed' oppositions <B781><date>:	2017.02.15
Kind code of the result from the examination on admissibility <B781><kind>:	Admissible opposition		
Name of Opponent <B781><snm>:	Teva Pharmaceutical Industries Ltd	EPO number of the Opponent <B781><iid>:	101506962
Address of Opponent <B781><addr><street>, <city>, <ctry>:	5 Basel Street P.O. Box 3190 49131 Petah Tiqva		
Name of Attorney/Agent of the opponent	Gallagher, Kirk James	EPO number of Attorney/Agent <B784><iid>:	100049136

<B784><snm>:			
Address of Attorney/Agent <B784><addr><street>, <city>, <ctry>:	D Young & Co LLP 120 Holborn London EC1N 2DY		

Serial number of the opposition <B781><dnum>:	02	Date of opposition, Date of receipt for 'filed' and 'admissible' oppositions, Date of legal effect for 'inadmissible' and 'deemed not, to be filed' oppositions <B781><date>:	2017.02.17
Kind code of the result from the examination on admissibility <B781><kind>:	Admissible opposition		
Name of Opponent <B781><snm>:	Polpharma S.A.	EPO number of the Opponent <B781><iid>:	101506959
Address of Opponent <B781><addr><street>, <city>, <ctry>:	Ul. Pelplinska 19 83-200 Starogard Gdanski		
Name of Attorney/Agent of the opponent <B784><snm>:	Bird & Bird LLP	EPO number of Attorney/Agent <B784><iid>:	101612690
Address of Attorney/Agent <B784><addr><street>, <city>, <ctry>:	Maximiliansplatz 22 80333 München		

Serial number of the opposition <B781><dnum>:	03	Date of opposition, Date of receipt for 'filed' and 'admissible' oppositions, Date of	2017.02.20
--	----	--	------------

		legal effect for 'inadmissible' and 'deemed not, to be filed' oppositions <B781><date>:	
Kind code of the result from the examination on admissibility <B781><kind>:	Admissible opposition		
Name of Opponent <B781><snm>:	Generics (U.K.) Limited	EPO number of the Opponent <B781><iid>:	101554369
Address of Opponent <B781><addr><street>, <city>, <ctry>:	Station Close Potters BarHertfordshire EN6 1TL		
Name of Attorney/Agent of the opponent <B784><snm>:	FRKelly	EPO number of Attorney/Agent <B784><iid>:	101394806
Address of Attorney/Agent <B784><addr><street>, <city>, <ctry>:	27 Clyde Road Dublin D04 F838		

Serial number of the opposition <B781><dnum>:	04	Date of opposition, Date of receipt for 'filed' and 'admissible' oppositions, Date of legal effect for 'inadmissible' and 'deemed not, to be filed' oppositions <B781><date>:	2017.02.20
Kind code of the result from the examination on admissibility <B781><kind>:	Admissible opposition		
Name of Opponent	Hamm&Wittkopp	EPO number of the	101617234

<B781><snm>:	Patentanwälte PartmbB	Opponent <B781><iid>:	
Address of Opponent <B781><addr><street>, <city>, <ctry>:	Jungfernstieg 38 20354 Hamburg		
Name of Attorney/Agent of the opponent <B784><snm>:	Hamm&Wittkopp Patentanwälte PartmbB	EPO number of Attorney/Agent <B784><iid>:	101574077
Address of Attorney/Agent <B784><addr><street>, <city>, <ctry>:	Jungfernstieg 38 20354 Hamburg		

Designated countries <B840>:

Kind of document <B130>:	Date of publication <B140>:	Country code <B840><ctry>:
B1	2018.04.04	NO

PCT <B860>&<B870>:
No PCT.

Citations <B560>:

Kind of document <B130>:	Type <B561> or <B562>:	Text <B561><text> or <B562><text>:
B1	PT citation	EP-A1- 1 897 537
B1	PT citation	WO-A-00/38676
B1	PT citation	WO-A-2005/014043
B1	PT citation	WO-A-2007/056546
B1	PT citation	US-A1- 2002 098 241
B1	PT citation	US-B1- 6 248 729

B1	Non PT citation	AULAKH ET AL: "An update on non-peptide angiotensin receptor antagonists and related RAAS modulators", LIFE SCIENCES, PERGAMON PRESS, OXFORD, GB, vol. 81, no. 8, 2 August 2007 (2007-08-02) , pages 615-639, XP022207851, ISSN: 0024-3205
B1	Non PT citation	SAYDAM M. & S. TAKKA: "Bioavailability file: Valsartan", FABAD J. PHARM. SCI., vol. 32, 1 January 2007 (2007-01-01), pages 185-196, XP002676967,
B1	Non PT citation	LUIS MIGUEL RUILOPE: "Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study", THELANCET, vol. 375, 10 April 2010 (2010-04-10), pages 1255-1266, XP002676955,